Guest: Fauad Hasad
Presenter: Neal Howard
Guests Bio: Fauad Hasan is the President and CEO at Bonti. He is a chemical engineer, with graduate degrees from University of Maryland, including MBA, Fauad comes with more than 17 years of experience in the Biopharmaceutical industry, Fauad Hasan is the President and CEO of Bonti, Inc. Until recently, he was the strategic and technical leader in the R&D group at Allergan, where he also served on the Global Product Development teams of top tier neurotoxins and ocular programs establishing overall drug development strategy from discovery to commercialization. This includes taking next generation Botox® molecules and ophthalmic drugs such as DARPin® through their product life cycle from proof of concept stage through late stage development and interaction with global regulatory agencies.
Fauad started his career at Regeneron Pharmaceuticals, where he was part of the group that developed manufacturing processes for IL and VEGF-Trap molecules, including Eylea ($1.5B drug for AMD and DME). He moved on to Baxter International working in various roles of increasing responsibilities in the areas of process development, manufacturing, plant engineering, and project management, catering to both internal and external client projects for therapeutic proteins, that included Mabs, in addition to blood clotting proteins (FVIII and FIX). Fauad is one of the pioneers of Single-use bioreactor (SUB) for the production of therapeutic proteins. He is a co-owner of several patents related to this technology.
Segment overview: Fauad Hasan, President & CEO at Bonti, a privately-held, clinical-stage biotechnology company, discusses its LANTERN clinical program aimed at relieving musculoskeletal pain and reducing the use of opioids using its neurotoxin platform.